Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US Enforcement 2019: Compounding, Opioids Top Priorities But Beware Of REMS Violations, Too

Dec 19 2018

• By Sue Sutter

James Burnham, deputy assistant attorney general in the Department of Justice’s Civil Division — Deputy Assistant AG James Burnham discusses DoJ enforcement priorities at FDLI. • Source: Sue Sutter

Related Content

Opioid Policy At US FDA: Over-Promising Or Overreacting?

Oct 25 2018

Opioid REMS Increases Nearly Six-Fold As US FDA Adds Immediate-Release Products

Sep 19 2018

From White House To White Oak: US FDA Taps Stacy Cline Amin For Chief Counsel Post

Sep 07 2018

Reimbursement Support Programs Create 'Holy Trinity' Of Enforcement Risk

Sep 29 2016

Novo's Victoza REMS Settlement Opens Another Legal Door For Off-Label Promotion Cases

Sep 07 2017

Aegerion <em>Juxtapid</em> Settlement Shows REMS Have Teeth: Alternate Route To Enforce Off-Label?

May 23 2016

Pharma May See Brighter Enforcement Environment After US Justice Department Policy Changes

Dec 18 2018

Related Companies

INSYS Therapeutics, Inc.

Novo Nordisk A/S

Aegerion Pharmaceuticals, Inc.

Additional Topics

United States Enforcement Legal Issues Advertising, Marketing & Sales Reimbursement Regulation BioPharmaceutical

More from Compliance

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window